FF-10832

FF-10832 is a novel liposomal formulation of the anti-cancer agent gemcitabine. Developed using Fujifilm's advanced nano-dispersion technology, it encapsulates water-soluble gemcitabine in uniform-sized (~80 nm) liposomes to enhance tumor-selective delivery and prolong drug exposure at the tumor site. This design leverages the enhanced permeability and retention (EPR) effect for improved accumulation in tumors while reducing systemic toxicity. Preclinical studies have shown that FF-10832 achieves higher plasma stability, greater tumor uptake, and superior antitumor activity compared to unencapsulated gemcitabine—even in models resistant to standard gemcitabine therapy. The mechanism involves both direct cytotoxicity from released gemcitabine and modulation of the tumor immune microenvironment via macrophage uptake and immune activation. Clinical development has focused on advanced solid tumors—including pancreatic cancer—and combination regimens with immune checkpoint inhibitors such as pembrolizumab[1][2][3][4][5][6].

Other names

Gemcitabine Liposome Injectionliposomal gemcitabine